Clinical Trial Update: Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies [Phase 1]

View source ↗

Summary

Phase 1 trial update of a genetically modified T-cell therapy targeting ROR1 in advanced malignancies, with terminated status and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Breast Cancer
• Chronic Lymphocytic Leukemia
• Hematopoietic and Lymphoid Cell Neoplasm
• Lung Non-small Cell Cancer
• Lung Non-small Cell Carcinoma
• Malignant Solid Neoplasm
• Mantle Cell Lymphoma
• Stage Iiia Lung Non-small Cell Cancer
• Stage Iiib Lung Non-small Cell Cancer
• Triple-negative Breast Carcinoma
• Unresectable Lung Non-small Cell Carcinoma

Drugs mentioned

• Genetically modified T-cell therapy targeting ROR1 (ROR1-directed T-cell therapy)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 1 | Status: TERMINATED | Results posted: 2022-08-31